Cytokine News and Research

RSS

Osteoarthritis research: an interview with Dr Deborah Mason, Cardiff University

Osteoarthritis is an extremely common condition affecting about 8 million people in the UK. The elderly are particularly susceptible, with up to 45% of people over 65 years, having the disease.

14 Aug 2013

Ensemble Therapeutics initiates research and development collaboration with Novartis

Ensemble Therapeutics, a biotechnology company developing Ensemblins, a novel class of small molecule therapeutics with the power of biologics, today announced the initiation of a two-part research and development collaboration with Novartis.

6 Aug 2013

Cyp11a1 enzyme is a potential target for treatment of deadly food allergy, say researchers

Researchers at National Jewish Health have identified an enzyme that is essential to the allergic reaction to peanuts. Blocking the enzyme's activity in sensitized mice prevented diarrhea and inflammation, and reduced levels of several proteins associated with allergies.

2 Aug 2013

Virginia Commonwealth University receives $1.8M grant to study biology of allergic disease

The National Institutes of Health has awarded Virginia Commonwealth University a grant totaling $1.8 million to study the biology of allergic disease - work which may one day point researchers to the development of therapies to fight asthma, allergy and inflammatory conditions such as rheumatoid arthritis, multiple sclerosis and heart disease.

18 Jul 2013

Poor sleep during pregnancy can disrupt immune processes and lead to lower birth weights

Poor sleep quality and quantity during pregnancy can disrupt normal immune processes and lead to lower birth weights and other complications, finds a University of Pittsburgh School of Medicine study published today in the journal Psychosomatic Medicine. Women with depression also are more likely than non-depressed women to suffer from disturbed sleep and to experience immune system disruption and adverse pregnancy outcomes.

18 Jul 2013

Research on activating Glial Cells to be presented at 7th Annual Pain Therapeutics Summit East

Linda Watkins, Ph.D., Distinguished Professor, Department of Psychology & Neuroscience and Center for Neuroscience, University of Colorado, Co-Chair, Advisory Board, Xalud Therapeutics, Inc. will present research on activating Glial Cells as part of the speaking faculty at the 7th Annual Pain Therapeutics Summit East in Boston, MA.

11 Jul 2013

Cancer immunotherapies promise to be a new tool in fight against cancer

Drugs that direct a cancer patient's immune system to eradicate her or his disease, known as cancer immunotherapies, promise to be a new tool in the fight against cancer. Since the Koch Institute's inception, exploring the close relationship between the immune system and cancer has been one of the Institute's priority research areas.

9 Jul 2013

New mechanism triggers chronic inflammation in Alzheimer's, atherosclerosis and type-2 diabetes

Researchers at NYU Langone Medical Center have discovered a mechanism that triggers chronic inflammation in Alzheimer's, atherosclerosis and type-2 diabetes. The results, published today in Nature Immunology, suggest a common biochemical thread to multiple diseases and point the way to a new class of therapies that could treat chronic inflammation in these non-infectious diseases without crippling the immune system.

2 Jul 2013

Idera Pharmaceuticals reports Phase 1 clinical trial results of IMO-8400

Idera Pharmaceuticals, Inc. announced results of a Phase 1 clinical trial of IMO-8400, a first-in-class antagonist of Toll-like Receptors 7, 8, and 9 being developed for potential applications in autoimmune and inflammatory diseases.

2 Jul 2013

Karo Bio extends research collaboration with Pfizer on RORgamma modulators

Karo Bio AB announced today the extension of its existing research collaboration with Pfizer Inc. on RORgamma modulators to the end of 2014. Pfizer will continue to provide full funding for the research costs.

26 Jun 2013

EULAR announces recipients of Meritorious Service Award

EULAR today announced the recipients of the 13th annual Meritorious Service Award at the opening of the European League Against Rheumatism Annual Congress.

14 Jun 2013

New study shows treatment with brodalumab demonstrates clinical response in subjects with PsA

A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that treatment with brodalumab demonstrates significant clinical response and an acceptable safety profile in subjects with psoriatic arthritis.

13 Jun 2013

Data points to potential role of immunosuppression in protecting organs from inflammation after injury

In the largest study of its kind, physicians from the Department of Surgery at the University of Maryland School of Medicine and the R Adams Cowley Shock Trauma Center at the University of Maryland Medical Center have determined that outcomes for traumatic injury in patients with organ transplants are not worse than for non-transplanted patients, despite common presumptions among physicians.

11 Jun 2013

Researchers show interleukin-22 guards against bacterial superinfections that can arise after influenza

Researchers from the Pasteur Institute, Lille, France have shown in a mouse model that interleukin-22 protects against bacterial superinfections that can arise following influenza.

31 May 2013

Lab-based skin test eliminates risk of adverse reactions to new drugs, cosmetics

A simple lab-based skin test which eliminates the risk of adverse reactions to new drugs, cosmetics and household chemicals has been developed by a Newcastle University, UK team.

28 May 2013

Understanding the role of dsRNA in antiviral host defense systems

Animals, insects, and plants use a variety of sensing mechanisms to detect invading pathogens such as viruses. One complex and effective antiviral defense system they share is based on recognition of double-stranded RNA, often produced when a virus invades a host cell.

20 May 2013

Study: VEGF inhibitor appears to improve glaucoma surgical outcomes

The most common cause of failure after glaucoma surgery is scarring at the surgical site, so researchers are actively looking for ways to minimize or prevent scar formation. Previous work had suggested that vascular endothelial growth factor (VEGF) activates fibrosis, whereas VEGF inhibition results in reduced scar formation and better surgical results.

18 May 2013